For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
search
Quick Order bolt
Request Quote sms
Applications
Lopinavir & Ritonavir Tablets USP (COVID-19) Kinetex 5 µm C8 150 x 4.6 mm
25916
Separation Mode: Reversed Phase
Reversed Phase
USP
C8
HPLC
Anti-HIV Agents
Pharmaceutical/Biopharmaceutical
Therapeutic / Clinical
Therapeutic / Clinical

Lopinavir & Ritonavir Tablets USP (COVID-19) Kinetex 5 µm C8 150 x 4.6 mm

zoom_in
Analytes
1Ritonavir
2Lopinavir
Details
Official Method: USP
LC Conditions (App ID: 25916)
Column:
Brand Name:
Kinetex
Part No:
Phase Name:
C8
System:
Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC
Sample Note:
Buffer = 4.1 g Potassium Phosphate monobasic in 1 L of Water Solution A = 50:50 ACN:Buffer Samples were dissolved and diluted in Solution A
Similar Applications
search
No Data
Phenomenex
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide
Danaher
Connect With Us
Phenomenex
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide

Products and Services

Products

Techniques

Industries

Quick Order

Support

Product Method Support

Product Troubleshooting

Contact Us

CQA CofA

Our company

About Phenomenex

Blog

News

Danaher Life Sciences

Terms and Conditions Privacy Statement Quality Policy Terms of Use Trademarks CA Supply Chains Act CA Consumer Privacy Act Cookie Policy Impressum
© 2024  Phenomenex Inc. All rights reserved.